UnitedHealth's Oxford Group Picks Praluent As First-Line PCSK9
This article was originally published in Scrip
The battle for US health insurance reimbursement of the roughly $14,000 annual cost of PCSK9 inhibitors continues with Oxford Health Plans, a UnitedHealthcare company, making Praluent (alirocumab) from Regeneron Pharmaceuticals and Sanofi its first choice for lowering LDL cholesterol beyond what's possible with generic statins.
You may also be interested in...
The launch of generic rosuvastatin offers yet another way to calculate the disappointing performance of the PCSK9 inhibitors.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.